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ABSTRACT 
Mitochondria are known to play crucial roles in normal cellular physiology and in more recent 
years they have been implicated in a wide range of pathologies. Central to both these roles 
is their ability to alter their shape interchangeably between two different morphologies: an 
elongated interconnected network and a fragmented discrete phenotype – processes which 
are under the regulation of the mitochondrial fusion and fission proteins, respectively. In this 
review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 (OPA1) in 
cardiovascular health and disease and we explore its role as a potential therapeutic target 
for treating cardiovascular and metabolic disease. 
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Introduction 
 
Cardiovascular disease (CVD) remains one of the leading causes of death and disability 
worldwide. Understanding the pathophysiology of CVD will help in the identification of novel 
therapeutic targets for treating CVD. The human heart beats on average 100,000 per day, a 
function which requires a constant energy supply. This is provided for by mitochondria, 
which are densely packed into, and occupy almost one third the volume of a cardiomyocyte. 
The role of mitochondria in cellular physiology extends far beyond the production of ATP 
required for normal contractile function, as they also play a variety of other essential roles 
including calcium signalling (1), reactive oxygen species (ROS) production (2-5), and the 
initiation of cell death (6). Central to these roles is the ability of mitochondria to alter their 
shape interchangeably between two different morphologies: an elongated interconnected 
network (mitochondrial fusion) and a fragmented discrete phenotype (mitochondrial fission). 
In this review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 
(OPA1) in cardiovascular health and disease and we explore its role as a potential 
therapeutic target for treating cardiovascular and metabolic disease. 
 
Mitochondrial morphology in cardiovascular health and disease 
 
Mitochondria are dynamic organelles which are able to change their shape and number 
according to the cell type, metabolic requirements, and extracellular stimuli. This 
phenomenon has been termed ‘mitochondrial morphology’ and is essential for the 
maintenance of a healthy mitochondrial network and normal cellular physiology. 
Mitochondria fusion occurs when neighbouring organelles fuse with each other enabling 
them to elongate and form interconnected networks. As well as this, mitochondria are able to 
fragment and separate from each other to form discrete units, a process known as 
mitochondrial fission. The changes in mitochondrial morphology are mediated by the 
mitochondrial fusion proteins (Mitofusins 1 and 2 [Mfn1 and 2] and optic atrophy protein 1 
[OPA1]) and the mitochondrial fission proteins (dynamin related peptide 1 [Drp1], human 
fission protein 1 [hFis1], mitochondrial fission factor [MFF], and mitochondrial dynamics 
proteins of 49kDa and 51kDa [MiD49/51]). The role of these mitochondrial shaping proteins 
has been comprehensively reviewed elsewhere (7-11). In this review article we will focus 
specifically on the role of OPA1 in cardiovascular health and disease.  
 
The discovery of OPA1  
 
In 1959, Kjer, a Danish ophthalmologist first described the condition now known as dominant 
optic atrophy (DOA), also called Kjer’s optic neuropathy (12). This condition is characterized 
by mitochondrial dysfunction and degeneration of the optic nerves causing impaired colour 
vision, reduced visual acuity, and in many cases blindness (12). It has an estimated 
prevalence of 1:50 000 in most countries and a prevalence as high as 1:10 000 in Denmark 
(13). It is an autosomal neurodegenerative disease which was later discovered in 2000 to be 
due to a mutation in the OPA1 protein (14, 15). OPA1 expression is tissue-specific with 
some of the highest levels of expression found in the retina, brain, liver, heart and skeletal 
muscle (14, 15). Its best known role is as a mediator of mitochondrial fusion, but it is clear 
that many of its effects extend beyond this and rely upon its pleiotropic non-fusion roles. 
Alternative splicing and proteolysis of the OPA1 protein allows these diverse functions and is 
reviewed next.  
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Proteolytic regulation of OPA1 function 
 
OPA1 function is determined by alternative splicing and post-translational modification, 
making the cellular processing of the OPA1 protein rather complex. OPA1 shares a number 
of common structural features with dynamins, including a GTPase domain, a middle domain, 
and GTPase effector domain (GED)(9). Alternative splicing of OPA1 generates eight OPA1 
isoforms, the expression of which varies according to the tissue (16). Human and murine 
tissues mainly express the OPA1 isoforms 1 and 7. The mitochondrial import sequence 
located at the NH2-terminal region of the OPA1 isoforms targets OPA1 to the mitochondria 
and is removed in the inter-membranous space (IMS) by the mitochondrial processing 
peptidase. This generates insoluble long forms of OPA1 (termed l-OPA1) anchored to the 
IMM (17, 18). The various forms of l-OPA1 possess either one or two cleavage sites: S1 
(which is present in all forms of l-OPA1) and S2 (which is only present in some forms of l-
OPA1).  
Following the mitochondrial import of the OPA1 isoforms, the constitutively active IMS AAA 
(i-AAA) protease, YME1L, cleaves those forms of l-OPA1 containing the S2 cleavage site 
generating soluble short forms of OPA1 (termed s-OPA1) within the IMS and loosely 
attached to the IMM. Further cleavage of s-OPA1 by presenilin associated rhomboid-like 
(PARL) results in small quantities of s-OPA1 in the IMS. Under conditions of cellular stress 
(such as H2O2 (19), valinomycin and oligomycin (20)), the zinc metalloprotease OMA1 
mediates the proteolysis of OPA1 at the S1 cleavage site resulting in the degradation of all 
forms of l-OPA1 to s-OPA1. The consequence of this is the inhibition of mitochondrial fusion 
(as this process requires the presence of both l-OPA1 and s-OPA1) resulting in unopposed 
mitochondrial fission and fragmented mitochondria (21, 22). The regulation of OPA1 function 
by these proteases and their interaction with each other is rather complex and has been 
reviewed in detail elsewhere (10, 23-25) – only an overview is provided here (see Figure 1).  
Yme1l mediates the proteolytic cleavage OPA1 at the S2 site (21). Genetic ablation of 
Yme1L result in mitochondrial fragmentation in a manner which is dependent on OPA1 (22). 
PARL (a mitochondrial rhomboid protease) has been reported to proteolyse the s-OPA1 
constitutively produced by Yme1L, generating a minor fraction of soluble s-OPA1 in the IMS 
that is required for the anti-apoptotic function of OPA1 (26, 27). OMA1 is an IMM protease 
which is constitutively active, although its activity is enhanced under the conditions of cellular 
stress such as mitochondrial membrane depolarization, thermal stress, oxidative stress and 
Bax/Bak initiated apoptosis (28). The activation of OMA1 is regulated by an amino terminal 
stress-sensor domain and is associated with its autocatalyic degradation, thereby limiting its 
activation to the period of cellular stress and allowing OPA1-mediated mitochondrial fusion 
to continue once the stress has subsided (20). A recent experimental study has shown that 
OMA1 cleaves itself to a short form of OMA1 (s-OMA1), which is degraded quickly, but is 
stabilized by mitochondrial membrane depolarization and during apoptosis, thereby allowing 
the cleavage of OPA1 under conditions of stress (29). Recent data suggests that an 
interaction between the mitochondrial proteases Yme1l and OMA1 may facilitate OPA1 
proteolysis in stressed mitochondria allowing the selected removal of damaged mitochondria 
by mitophagy. In response to oxidative stress Yme1l has been shown to be degraded in a 
manner which shown to be dependent on OMA1, thereby augmenting OPA1 proteolysis 
(30). Prohibitin, a IMM protein, has also been shown to regulate OPA1 processing (31). Loss 
of prohibitin subunit 2 (Phb2) resulted in the loss of l-OPA1, the result of which was 
abnormal cristae, reduced cell proliferation and increased sensitivity to apoptosis. The actual 
mechanism through which Phb2 regulates OPA1 processing remains unclear. Recently, 
Sood et al (32) have described a novel form of OPA1 processing in response to nutrient 
limitation, in which two novel regulatory C-terminal fragments of OPA1 are generated by a 
cysteine protease in a manner which is independent of OMA1 and PARL. Interestingly this 
novel type of cellular processing of OPA1 was shown to be dependent on the association of 
OPA1 with MFN2 present at contact sites between mitochondria and endoplasmic reticulum. 
The potential significance of this form of OPA1 processing is not clear and is discussed in a 
later section (32).  
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Other regulators of OPA1 function 
 
In addition to proteolytic cleavage, OPA1 has been found to be regulated by several other 
post-translational modifications, thereby complicating further the regulation of OPA1 
function. Makino et al (33) have shown in neonatal cardiomyocytes that in the presence of 
high glucose, O-GlcNAcylation of OPA1 suppressed OPA1 activity resulting in mitochondrial 
fission. The potential implications of this for the diabetic heart are discussed in a later 
section. OPA1 activity has recently been reported to be modified by acetylation (34). In 
response to cellular stress, the class III histone mitochondrial deacetylase, Sirtuin 3, has 
been shown to deacetylate OPA1 at the lysine 926 and 931 residues, increasing its GTPase 
activity and promoting mitochondrial fusion and protection against cell death (34).  The 
relevance of this has been explored in the context of cardiac disease and diabetes in a later 
section (34). Using a genome-wide RNA interference (RNAi) screen, Norton et al (35) have 
recently identified reactive oxygen species modulator 1 (ROMO1) to be a novel regulator of 
mitochondrial fusion and normal cristae morphology. They found that the oligomerization of 
OPA1 required for its anti-apoptotic effect against oxidative stress was dependent on the 
formation of mitochondrial ROMO1 complexes. The exact interaction between ROMO1 and 
OPA1 is unclear, but it has been proposed that by attenuating oxidative stress, ROMO1 acts 
to reduce the activation of OMA1 thereby preventing the proteolytic cleavage of OPA1 (36). 
Finally, Hypoxia-induced gene domain protein 1 (Higd-1a), an IMM protein which has been 
reported to suppress mitochondrial cytochrome c release and inhibit apoptotic cell death 
under conditions of hypoxia, has been recently linked to OPA1 function (37, 38). It has been 
shown to bind to and prevent the cleavage of l-OPA1 into s-OPA1, thereby attenuating 
cytochrome C release and inhibiting carbonyl cyanide-4-phenylhydrazone (FCCP)-induced 
mitochondrial fission and cell death (38). The mechanism through which Higd-1a prevents 
the proteolysis of OPA1 remains to be determined. 
 
OPA1 as a mitochondrial fusion protein 
 
OPA1 is best known for its role as a mitochondrial fusion protein in which it hydrolyses GTP 
to fuse IMMs of adjacent mitochondria (39). Song et al have shown that functional OPA1 is 
maintained by constitutive processing and that both the long and short OPA1 forms need to 
be present for mitochondrial fusion to occur (21). Experimental studies have shown that 
ablating or reducing OPA1 protein levels results in the breakdown of integrated 
mitochondrial networks resulting in mitochondrial fragmentation (40, 41). Interestingly, it has 
been demonstrated that the OMM fusion protein, Mfn1 but not Mfn2, is required for OPA1 to 
mediate mitochondrial fusion, although the reasons for this are not clear (42). In this pro-
fusion role, OPA1 is required to maintain a healthy mitochondrial network. Depolarization of 
the mitochondrial membrane potential in damaged mitochondria was found to increase the 
activity of OMA1 which in turn cleaved all forms of l-OPA1 into s-OPA1 thereby inhibiting 
mitochondrial fusion and permitting mitochondrial fragmentation, allowing the selective 
removal of damaged mitochondria by mitophagy (43, 44). 
 
A recent study by Mishra et al (45) has investigated the link between mitochondrial fusion 
and mitochondrial function as measured by the level of oxidative phosphorylation 
(OXPHOS). They found that when oxidative respiration was stimulated, Yme1l mediated 
proteolysis of l-OPA1 was enhanced. The result of this was increased IMM fusion, providing 
further support for the dependency of mitochondrial fusion on s-OPA1. Another study has 
shown that OXPHOS is able to suppress stress-induced mitophagy and maintain 
mitochondrial fusion by attenuating OMA1-dependent cleavage of OPA1 and reducing Drp1 
fission activity (44). In contrast to these findings, a recent experimental study has questioned 
this paradigm reporting that l-OPA1 alone is sufficient to mediate IMM fusion and that s-
OPA1 may actually associate with the OMM and induce mitochondrial fission (19).  
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Pleiotropic non-fusion roles of OPA1 
 
In addition to its role as a pro-fusion mitochondrial protein, OPA1 is known to have several 
pleiotropic, non-fusion roles which have been recently shown to impact on cristae 
morphology and mitochondrial respiratory efficiency.  
  
Cristae remodelling and mitochondrial apoptosis   
 
The down-regulation of OPA1 and the over-expression of OPA1 have been reported to 
induce or prevent apoptosis respectively, suggesting that OPA1 has an anti-apoptotic effect 
(41, 46). In this regard, and independent of its role as a mediator of IMM fusion, OPA1 has 
been shown to regulate mitochondrial cristae morphology, cytochrome C distribution, and 
apoptotic cell death. It is well-established that cristae remodelling (cristae fusion and 
widening of the cristae junction), by tBID is required for the redistribution of cytochrome C 
from the intra-cristal space into the IMS and the initiation of apoptosis (47). By ‘stapling’ 
these cristae junctions closed, oligomers formed between PARL-proteolysed s-OPA1 in the 
IMS and insoluble l-OPA1 isoforms anchored to the IMM, have been shown to prevent the 
redistribution of cytochrome C and inhibit apoptotic cell death (46).  
 
Cristae remodelling and mitochondrial respiratory efficiency 
     
The respiratory complexes of the electron transport chain (ETC) are not arranged at random 
within the IMM, but are instead assembled into respiratory chain supercomplexes (RCS), the 
arrangement which facilitates the transfer of electrons between the respiratory complexes, 
thereby improving mitochondrial respiratory efficiency (reviewed in (48)). The regulation of 
cristae morphology by OPA1 has been recently shown to impact on the formation of RCS 
and mitochondrial energy production. Using genetic manipulation of OPA1, Cogliati et al (49) 
have demonstrated that the stability and assembly of RCS, mitochondrial respiratory 
efficiency, and mitochondria-dependent cell growth, were critically dependent on cristae 
morphology. These findings implicate OPA1 as a critical regulator of mitochondrial 
respiration and therefore a therapeutic target for modulating mitochondrial energy 
production.  
 
OPA1 and cardiovascular and metabolic diseases 
 
OPA1 has recently been investigated in a number of cardiovascular and metabolic diseases. 
In general, it appears to play a beneficial role in these settings, positioning OPA1 as a 
potential therapeutic target in the novel treatment of these medical conditions (see Figure 2).   
 
OPA1 and heart failure 
 
One of the first experimental studies to investigate the role of OPA1 in the heart was by 
Chen et al (50). These authors observed that myocardial levels of OPA1 were reduced in 
ischemic heart failure patients and in a rat model of ischemic heart failure (50). These 
findings were associated with presence of small fragmented mitochondria and increased 
apoptotic cell death (50). The reduction of myocardial OPA1 was shown to affect all forms of  
l-OPA1 and s-OPA1 and was thought to be due to post-translational modification as the 
levels of OPA1 mRNA expression were not altered (50). Importantly, the protein levels of the 
other mitochondrial fusion proteins Mfn1 and Mfn2 and the fission proteins Drp1 and hFis1 
were unchanged in the presence of ischemic heart failure (50). In contrast, in myocardial 
tissue harvested from patients with dilated cardiomyopathy, levels of OPA1 were unchanged 
with increased myocardial levels of Mfn1, Mfn2 and Drp1 (50).  
 
The endogenous role of OPA1 in the heart has been recently investigated in mice partially 
deficient in OPA1 and resulted in a late onset cardiomyopathy at 12 months with a decrease 
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in cardiac output, reduced fractional shortening, and a blunted response to a β-adrenergic 
stimulus - findings which were associated with mitochondrial fragmentation, impaired 
mitochondrial respiration due to decreased complex I and IV activity, increased oxidative 
stress (down-regulation of the antioxidant enzymes Gpx3 and Gstk1), attenuated calcium 
transients, and a reduction in mitochondrial DNA copy number (51).  
 
The mechanism for the down-regulation of OPA1 in heart failure is unclear and the role this 
plays in the pathophysiology of ischemic heart failure is not known. Whether the reduction in 
myocardial OPA1 contributes to the metabolic abnormalities and enhanced apoptotic cell 
death characteristic of heart failure remains to be determined. 
 
OPA1 and ischemia/reperfusion injury 
 
Several experimental studies have demonstrated that cardiac ischemia induces 
mitochondrial fission and that genetic or pharmacological inhibition of the mitochondrial 
fission protein, Drp-1, limited MI size (52-54). The role of OPA1 in the cellular response to 
I/R injury has also been investigated. Chen et al (50) demonstrated in H9C2 cells that 
simulated ischemia reduced OPA1 protein levels, increased mitochondrial fragmentation, 
and worsened apoptotic cell death. The siRNA knockdown of OPA1 exacerbated these 
effects of simulated ischemia (50). However, the over-expression of OPA1 did not appear to 
protect against ischemia-induced apoptosis and actually worsened it (50). In contrast to 
these findings, An et al (38) observed that OPA1 overexpression was protective against a 
hypoxic insult in HEK293T cells. Furthermore, Chen et al (51) noted that murine 
cardiomyocytes isolated from adult mice were more susceptible to cell death induced by 
simulated I/R injury suggesting a cardio-protective role for OPA1.  
 
A recent experimental study investigating the role of OPA1 in I/R injury in the murine kidney 
has implicated OMA1 as a potential therapeutic target. Xiao et al (55) demonstrated that the 
genetic ablation of OMA1 protected renal proximal tubular cells against the detrimental 
effects of I/R injury in terms of preventing OPA1 proteolysis, inhibition of mitochondrial 
fragmentation, less cytochrome c release, and attenuated apoptotic cell death. Whether 
targeting OMA1 plays a similar protective role in hearts subjected to I/R injury remains to be 
determined.  
 
Sanjuán Szklarz & Scorrano (26) have recently suggested that mild heat stress induced the 
PARL-mediated proteolysis of OPA1 and the accumulation of soluble s-OPA1 within the 
IMS, which then protected cells against a subsequent lethal heat shock, suggesting that 
OPA1 may be involved in mediating a ‘conditioning’ form of protection. Whether OPA1 plays 
a role as a mediator of conditioning the heart to resist lethal I/R injury is an interesting 
possibility which needs to be investigated.     
 
OPA1 and left ventricular hypertrophy 
 
OPA1 has been recently investigated in the setting of left ventricular hypertrophy (LVH) 
using adult mice partially deficient in OPA1 (56). Although these mice appeared to have no 
significant cardiac phenotype at baseline, these mice were shown to be more susceptible to 
total aortic constriction, developing twice the extent of LVH, when compared to wild-type 
mice (56). These findings were associated with clustering of large mitochondria with 
abnormal cristae morphology which were demonstrated to be resistant to calcium-induced 
mitochondrial permeability transition pore (MPTP) opening. Overall this data appears to 
suggest that OPA1 is protective against LVH but the mechanism for this beneficial effect 
remains unknown.  
 
Samant et al (34) have found that myocardial OPA1 was hyper-acetylated in LVH induced by 
angiotensin II or total aortic constriction, findings which were associated with reduced OPA1 
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activity and mitochondrial fragmentation. In that study it was suggested that under basal 
conditions mitochondrial Sirtuin 3 deacetylates OPA1, thereby preserving the latter’s function 
and maintaining mitochondrial fusion. Contrasting findings were, however, reported in a 
separate study which showed that total OPA1 expression was significantly increased in the 
compensatory LVH characteristic of the spontaneous hypertensive rat model (57).  
 
OPA1 in cardiac development and cardiomyocyte differentiation 
 
Mice completely deficient in OPA1 die in utero, suggesting that OPA1 plays a critical role in 
embryonic development and maintenance of mitochondrial function (58). Cardiac-specific 
RNA- knockdown of OPA1 in the heart tube of Drosophila had the following detrimental 
effects; mitochondrial clustering, fragmentation, a 30% decrease in mitochondrial size - 
features which were associated with severe contractile impairment, cardiac dilatation and 
death, underscoring the requirement of OPA1 in cardiac development (59). Genetic ablation 
of OPA1 in Zebrafish was shown to reduce both cardiac contractions and heart rate (60). 
The accumulated evidence suggests that OPA1 is a critical regulator of cardiac 
development, presumably as it is required to mediate the organisation of the mitochondrial 
network needed to provide the increased energy requirements required to support this 
critical process. OPA1 has also been shown to play a critical role in the differentiation of 
embryonic stem cells into cardiomyocytes. Kasahara et al (61) demonstrated that the genetic 
inhibition of Mfn2 and OPA1 interrupted cardiomyocyte differentiation by inhibiting 
mitochondrial fusion through a complex pathway involving calcium-induced activation of 
calcineurin and enhanced Notch signalling. 
 
OPA1 and cardio-metabolic disease 
 
Diabetes is one of the major risk factors for developing CVD and its prevalence is increasing 
worldwide. In the presence of high glucose, abnormalities in mitochondrial shape and 
function have been shown to occur. These abnormalities coincide with changes in 
mitochondrial morphology, characterized by Drp-1 dependent mitochondrial fission which 
results in mitochondrial dysfunction, the mitochondrial production of ROS, MPTP opening 
and apoptotic cell death (62). A propensity to apoptosis and increased susceptibility to 
MPTP opening has also been described in adult cardiac mitochondria isolated from the 
diabetic murine heart (63). Makino et al (64) has demonstrated that mouse coronary 
endothelial cells isolated from the diabetic murine heart had reduced levels of OPA1 and 
evidence of mitochondrial fragmentation. Furthermore, OPA1 expression and fusion were 
both found to be impaired in diabetic patients (65). 
 
The aetiology for the observed mitochondrial fission which occurs in response to the high 
glucose remains unclear. A number of potential mechanisms have been proposed: (1) In 
neonatal cardiomyocytes it has been shown that in the presence of high glucose, O-
GlcNAcylation of OPA1 occurs, the consequence of which was suppression of OPA1 activity 
resulting in mitochondrial fission and dysfunction (33). Overexpression of GlcNAcase 
decreased OPA1 protein O-GlcNAcylation and significantly increased mitochondrial 
elongation (33). Moreover, OPA1 overexpression was able to prevent the changes in 
mitochondrial morphology induced by the hyperglycemia; (2) In the diabetic heart, OPA1 has 
been shown to be hyper-acetylated, reducing its activity and resulting in mitochondrial 
fragmentation (34).  
 
Parra et al (66) have reported in neonatal rat cardiomyocytes that treatment with insulin 
increased OPA1 protein levels, induced mitochondrial fusion, increased mitochondrial 
membrane potential, and augmented both intracellular ATP levels and oxygen consumption. 
The effect of OPA1 on mitochondrial function was shown to be mediated by the activation of 
the Akt-mTOR-NFκB pathway in a manner which was shown to be dependent on OPA1 (66). 
The physiological significance of this effect of insulin on mitochondrial morphology and 
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metabolism is unclear and remains to be investigated. The role for OMA1 has been 
investigated by Quirós et al (67), who found that glucose homeostasis was altered in the 
OMA1 mutant mice with the development of insulin resistance, suggesting that in the 
presence of diabetes, changes in OMA1 and OPA1 activity may contribute to the acquisition 
of insulin resistance in this condition.  
 
 Whether the down-regulation of OPA1 in the presence of diabetes contributes to the 
mitochondrial fragmentation observed in the diabetic heart remains to be determined. The 
overexpression of OPA1 may be a therapeutic strategy for preventing the mitochondrial 
fission and dysfunction which occurs in the diabetic heart, thereby preventing the cardiac 
dysfunction observed in diabetic cardiomyopathy. In this regard, the over-expression of 
OPA1 has been shown to improve mitochondrial morphology in coronary endothelial cells 
isolated from a diabetic heart supporting the notion that OPA1 may be a potential therapeutic 
target to improve cardiac dysfunction in diabetes (33, 64). 
 
Pharmacological inhibition of OMA1 as a therapeutic strategy  
 
The accumulated data outlined previously suggests that the down-regulation of OPA1 may 
contribute to the pathogenesis of a number of different cardiovascular and metabolic 
diseases. In terms of a viable therapeutic approach experimental studies suggest that the 
genetic inhibition of OMA1 can increase levels of OPA1 and protect the heart against cellular 
injury, supporting pharmacological inhibition of OMA1 as a therapeutic strategy for treating 
cardiovascular and metabolic disease. While non-specific zinc chelators, such as o-
phenanthroline, have been used in various studies to inhibit OMA1 activity and upregulate 
OPA1 (68-70), a more specific inhibitor of OMA1 needs to be discovered in order to make 
this therapeutic approach viable for the treatment of cardiovascular disease. The other issue 
to consider will be the possible detrimental effects of chronically upregulating OPA1 using 
long-term therapy with OMA1 inhibitors, and this limitation may restrict this therapeutic 
approach to conditions in which short-term OPA1 upregulation is beneficial.  
 
Summary and conclusions 
 
Cardiovascular and diabetes are the leading causes of death and disability today and new 
therapeutic targets are therefore required to discover novel therapies for treating these 
medical conditions and improving clinical outcomes in this patient group. Abnormalities in 
mitochondrial function are known to contribute to a number of cardiovascular conditions. In 
this regard, changes in mitochondrial morphology have been demonstrated to impact on 
mitochondrial function in cardiovascular health and disease. OPA1, a mitochondrial fusion 
protein in the IMM, is known to have a role which extends beyond its pro-fusion function. It 
has pleiotropic effects on cristae morphology which are critical to its effects on preventing 
apoptotic cell death and maintaining mitochondrial respiratory efficiency. Maintaining 
physiological levels of OPA1 protein has been shown to be important in cardiovascular 
health (cardiac development and cardiomyocytes differentiation), while down-regulation of 
OPA1 protein has been reported in cardiovascular disease (heart failure, 
ischemia/reperfusion injury, left ventricular hypertrophy and diabetes). Therefore, preserving 
OPA1 protein provides a novel therapeutic strategy for treating patients with cardiovascular 
disease, and this may potentially be achieved by pharmacological targeting of OMA1.   
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Abbreviations 
 
CVD          cardiovascular disease 
OPA1        optic atrophy protein 1 
ATP           adenosine triphosphate 
ETC           electron transport chain 
OXPHOS   oxidative phosphorylation 
ROS           reactive oxygen species 
MFN           mitofusin 
DRP           dynamin-related protein 
MFF           mitochondrial fission factor 
I/R              ischemia/reperfusion injury 
MPTP        mitochondrial permeability transition pore 
TAC           trans-aortic constriction 
DOA          dominant optic atrophy 
MIS           mitochondrial import sequence 
MPP          mitochondrial processing peptidase 
RCC          respiratory chain complexes 
RCS          respiratory chain supercomplexes 
LVH           left ventricular hypertrophy 
ROMO1     reactive oxygen species modulator 1 
FCCP        carbonyl cyanide-4-phenylhydrazone 
IMM           inner mitochondrial membrane 
OMM         outer mitochondrial membrane 
PARL         presenilin associated rhomboid like 
I/R              ischemia/reperfusion 
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Figure 1 
Proteolytic regulation of OPA1 
This simplified scheme illustrates the regulation of OPA1 function by proteolysis in 
mammalian tissue. Alternative splicing of the OPA1 protein yields eight OPA1 isoforms - 
human and murine tissue predominantly express the OPA1 isoforms 1 and 7.  Both these 
OPA1 isoforms have a S1 cleavage site (exon 5) whereas only OPA1 isoform 2 has a S2 
cleavage site (exon 5b). Under basal conditions, the constitutive proteolysis of the OPA1 
isoform 2 at the S2 cleavage site results in un-cleaved long OPA1 (l-OPA1) from OPA1 
isoform 1 and short OPA1 (s-OPA1) from OPA1 isoform 7, both of which are required for: (1) 
fusion of the inner mitochondrial membranes (IMM); (2) ‘stapling’ the cristae junctions closed 
to prevent cytochrome C redistribution from the cristae to the inter-membranous space 
(IMS), thereby inhibiting apoptosis; (3) maintaining cristae morphology so as to allow the 
formation of respiratory complex super-complexes (RCS) and efficient mitochondrial 
respiration. In contrast, under conditions of stress (mitochondrial membrane depolarization 
and ATP depletion, heat-stress, oxidative stress and apoptotic signals) the regulated 
proteolysis of the two OPA1 isoforms at the S1 cleavage site results in the proteolysis of all 
long OPA1 (l-OPA1) to short OPA1 (s-OPA1), the consequences of which include: (1) the 
inhibition of mitochondrial fusion thereby allowing un-opposed mitochondrial fission and the 
selected removal of damaged mitochondria by mitophagy; (2) the opening of the cristae 
junctions (black arrows) and the redistribution of cytochrome C from the cristae to the IMS, 
thereby initiating apoptosis; (3) abnormal cristae morphology thereby disrupting the 
formation of RCS and impairing mitochondrial respiratory efficiency.  
 
Figure 2 
 
Major cardiovascular and metabolic effects of OPA1  
This figure highlights the major cardiovascular and metabolic conditions in which OPA1 has 
been investigated and implicated.  
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Table 1. Overview of the main findings investigating the role of OPA1 in cardiovascular and 
metabolic disease. 
Setting Study   Model Outcome 
Cardiac development 
and cardiomyocyte 
differentiation 
 
Kasahara et al 2013 
 
 
Rahn et al 2013 
 
 
Dorn et al 2011 
 
Mouse ESCs 
 
 
 
Zebrafish 
 
 
Drosophila 
Cardiac development arrested upon gene 
trapping OPA1  
 
 
OPA1 knockdown reduces cardiac 
contractions and heart rate  
 
Impaired cardiac contraction + dilatation 
Left ventricular 
hypertrophy 
 
Piquereau et al 2012 
 
Tang et al 2014 
OPA1+/- 
knockout mice 
 
Spontaneously 
hypertensive rat 
(SHR) 
 
Hypertrophy and reduced ejection fraction in 
OPA1+/- knockout mice  
 
OPA1 down-regulated in SHR model 
Heart Failure 
 
Chen L et al 2009 
 
 
 
 
Chen et al 2012 
Murine and 
human heart 
failure 
 
 
OPA1+/- 
knockout mouse 
OPA1 protein levels reduced in these 
models. Reduced cardiac output, fractional 
shortening and contraction in OPA1+/- 
knockout mice 
 
These mice develop late-onset 
cardiomyopathy 
 
Ischemia/reperfusion 
injury 
 
 
 
Chen L et al 2009 
  
 
An et al 2011 
H9c2 cells 
 
 
HEK293T cells 
OPA1 levels reduced after simulated 
ischemic insult 
 
OPA1 over expression is protective 
simulated ischemic insult 
 
 
 
Chen L et al 2012 
 
OPA1+/- 
knockout mouse 
 
Less cell death after IRI in OPA1+/- knockout 
cardiomyocytes  
 
Diabetes and 
metabolic disease 
Parra et al 2014 
 
 
 
Quirós et al 2012 
 
 
Makino et al 2010 
Neonatal 
cardiomyocytes 
 
 
OMA1 KO 
mouse 
 
Type I diabetic 
mouse 
Insulin-mediated fusion lost when OPA1 
silenced 
 
 
Altered glucose homeostasis and insulin 
resistance in OMA1 KO  
 
Over-expression of OPA1 improves 
morphology of mitochondria from diabetic 
murine coronary endothelial cells 
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Table 2. Summary of the main post-translational modifications of OPA1 protein. 
Modification Type Effector Result 
Proteolysis 
 
 
 
 
 
 
 
 
Acetylation 
 
 
Acylation 
 
 
Other 
PARL 
 
OMA1 
 
 
YME1L 
 
 
 
SIRT3 
 
 
O-GlcNAcylation 
 
 
Higd1a 
 
 
ROMO1 
Regulates cytochrome c release 
 
Decreases l-OPA1 upon ATP 
depletion/loss of ∆Ѱm 
 
Cleaves to maintain balance of l-OPA1 
and s-OPA1. Increased with higher 
levels of OXPHOS 
 
Improves OPA1’s GTPase activity upon 
stress 
 
Suppresses OPA1 activity in presence 
of high levels of glucose 
 
Preserves OPA1 function by binding to 
l-OPA1 under hypoxic conditions 
 
Facilitates OPA1 oligomerization 
 
 
